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Background: The efficacy of durable polymer drug-eluting stents (DES) is delivered at the expense of delayed healing of the stented vessel. 
Biodegradable polymer DES aim to avoid this shortcoming and may potentially improve long-term clinical outcomes, with benefit expected to accrue 
over time. To compare long-term outcomes in patients treated with biodegradable polymer DES versus durable polymer sirolimus-eluting stents 
(SES).
Methods: We pooled individual patient data from three large-scale multicenter randomized clinical trials (ISAR-TEST 3, ISAR-TEST 4, and LEADERS) 
comparing biodegradable polymer DES with durable polymer SES and assessed clinical outcomes during follow-up through four years. Primary 
efficacy endpoint was target lesion revascularization; primary safety endpoint was definite stent thrombosis; secondary safety endpoint was the 
composite of cardiac death or myocardial infarction.
Results: Of 4,052 patients included in the present analysis, 2,358 were randomly assigned to treatment with biodegradable polymer DES 
(sirolimus-eluting, N=1,501; biolimus-eluting, N=857) and 1,704 patients to durable polymer SES. No heterogeneity across the trials was observed 
in analyses of the primary and secondary endpoints. At four years, the risk of target lesion revascularization was significantly lower among patients 
treated with biodegradable polymer DES versus durable polymer SES (hazard ratio 0.82, 95% CI 0.68-0.98, P=0.029). In addition the risk of stent 
thrombosis was significantly reduced with biodegradable polymer DES versus durable polymer SES (hazard ratio 0.56, 95% CI 0.35-0.90, P=0.015), 
driven by a lower risk of very late stent thrombosis (hazard ratio 0.22, 95% CI 0.08-0.61, P=0.004). In keeping with this, in landmark analysis at 1 
year, the composite of cardiac death or myocardial infarction was lower for patients treated with biodegradable polymer DES versus durable polymer 
SES (hazard ratio 0.73, 95% CI 0.53-1.00, P=0.050).
Conclusions: Biodegradable polymer DES improve safety and efficacy compared with durable polymer SES during long-term follow-up to 4 years. 
